PARLIAMENTARY WRITTEN QUESTION
Dinutuximab Beta (13 June 2018)
Question Asked
Asked by:
Helen Hayes (Labour)
Answer
Departmental officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence, and have had a number of discussions about the ongoing technology appraisal of dinutuximab beta for the treatment of high-risk neuroblastoma.
Answered by:
Steve Brine (Conservative)
21 June 2018
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.